Close Menu

NEW YORK (360Dx) – NeoGenomics on Thursday priced its previously announced public offering of 9.8 million shares of its common stock at $12.75 per share.

Gross proceed from the offering are expected to be approximately $125 million.

NeoGenomics has granted the underwriters a 30-day option to purchase up to 1.47 million additional shares of common stock at the public offering price, less underwriting discounts and commissions.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Feb
23
Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Feb
24
Sponsored by
SCHOTT MINIFAB

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints.